Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Sofie Berg"'
Autor:
Laurent Peyrin‐Biroulet, Subrata Ghosh, Scott D. Lee, Wan‐Ju Lee, Jenny Griffith, Kori Wallace, Sofie Berg, Xiaomei Liao, Julian Panes, Edward V. Loftus, Edouard Louis
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:496-508
Crohn's disease has a substantial negative impact on health-related quality of life (HRQoL).To examine the effects of risankizumab on HRQoL in Crohn's disease METHODS: We analysed data from patients with Crohn's disease from 12-week induction trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6848362ba9ea542d861d394a95c9b8b3
https://doi.org/10.1111/apt.17242
https://doi.org/10.1111/apt.17242
Autor:
Marc Ferrante, Laurent Peyrin-Biroulet, Axel Dignass, David T. Rubin, Silvio Danese, Geert D’Haens, Kristina Kligys, Sofie Berg, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Toshimitsu Fujii, Remo Panaccione, Ana Echarri Piudo
Publikováno v:
Gastroenterología y Hepatología. 46:S152
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c386408acf8bb3df4ff62e8aaf56ec38
https://doi.org/10.1016/s0210-5705(23)00252-2
https://doi.org/10.1016/s0210-5705(23)00252-2
Autor:
Marc Ferrante, Laurent Peyrin-Biroulet, Axel Dignass, David T. Rubin, Silvio Danese, Geert D’Haens, Kristina Kligys, Sofie Berg, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Toshimitsu Fujii, Remo Panaccione
Publikováno v:
American Journal of Gastroenterology. 117:e498-e499
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07639604da7b79271a092c2eeb6cead1
https://doi.org/10.14309/01.ajg.0000859500.54469.44
https://doi.org/10.14309/01.ajg.0000859500.54469.44
Autor:
Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G Feagan, Tadakazu Hisamatsu, Allen Lim, James O Lindsay, Edward V Loftus, Julián Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T Rubin, William J Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D'Haens
Publikováno v:
The Lancet, 399(10340), 2031-2046. Elsevier Limited
Background: There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e49b5f7038521294b69cf744c4fbd1
https://pure.amc.nl/en/publications/risankizumab-as-maintenance-therapy-for-moderately-to-severely-active-crohns-disease(a545e349-2239-4e02-8ea2-d744c64bcc91).html
https://pure.amc.nl/en/publications/risankizumab-as-maintenance-therapy-for-moderately-to-severely-active-crohns-disease(a545e349-2239-4e02-8ea2-d744c64bcc91).html
